The study of inherited genetic differences in drug metabolic pathways which can affect individual responses to drugs, both in terms of therapeutic effect as well as adverse effects. To simplify, the Pharmacogenetics Testing helps you make informed decisions regarding your medication.
You are unique So is your DNA and drug metabolism. In that picture, your medications too should be unique for you. PGx testing gives you a peep into how your body metabolizes certain drugs, in addition to identifying drugs that may not be suitable for you or may have adverse to severe impact on your health.
Through Pharmacogenetics testing, it becomes possible to understand how your genetic uniqueness responds to the drugs you have been prescribed. Your PGx test report allows you to avoid drugs that could be unsafe for you.
"In the United States, there are more than 100,000 deaths annually related to adverse drug effects. According to the Food and Drug Administration, over 700,000 Americans have serious consequences as the result of adverse drug reactions. An estimated 2 million hospitalizations occur yearly as the result."
This panel helps determine the risk of thrombosis or prothrombin deficiency. It can also help determine the therapeutic value of commonly used drugs for cardiovascular conditions.
Genes included: CYP2C19, CYP2D6, CYP2C9, VKORC1, CYP3A4, CYP3A5, Factor II, Factor V, MTHFR
This panel allows physicians to make individualized analgesic selections and dose and mitigate regulatory agency scrutiny by providing additional clinical decision-making evidence for several Schedule-II narcotics.
Genes included: COMT, CYP1A2, CYP2C19, CYP2C9, CYP2D6, OPRM1
This panel helps predict potential variability, achieve therapeutic benefits quickly, and minimize adverse drug reactions. Currently, 30 Psychotropics are required by FDA to include genetic information, dosage and administration, warnings and precautions, drug interactions, clinical pharmacology, contraindications, and adverse drug reactions.
Genes included: COMT, CYP1A2, CYP2C19, CYP2B6, CYP2D6, ANK1/DRD2, MTHFR, OPRM1
This panel helps identify inherited coagulation pathway changes that increase thrombosis risk and determine appropriate anti-coagulation therapy.
Genes included: CYP2D6, VKORC1, CYP2C9, MTHFR, Factor II, Factor V
This panel allows a patient and his or her physician to understand how genetics is involved in regulating the blood clotting pathways by directly identifying changes in DNA that are responsible for coagulation or pathways that contribute to increased risk of thrombosis and cardiovascular disorders.
Genes included: Factor II, Factor V, MTHFR